(19)
(11) EP 4 823 609 A1

(12)

(43) Date of publication:
21.10.2026 Bulletin 2026/43

(21) Application number: 24904887.7

(22) Date of filing: 12.12.2024
(51) International Patent Classification (IPC): 
A61K 39/12(2006.01)
C07K 14/005(2006.01)
A61P 31/14(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 39/12; C07K 14/005; A61P 31/14; C12N 2760/10022; C12N 2760/10034; A61K 2039/54; A61K 2039/55511; A61K 2039/55566; A61K 2039/545; A61K 2039/575
(86) International application number:
PCT/US2024/059824
(87) International publication number:
WO 2025/128854 (19.06.2025 Gazette 2025/25)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 12.12.2023 US 202363608980 P
12.09.2024 US 202463693882 P

(71) Applicants:
  • The Methodist Hospital
    Houston, TX 77030 (US)
  • Board of Regents, The University System of Texas
    Austin, TX 78701 (US)

(72) Inventors:
  • MCLELLAN, Jason, Scott
    Austin, Texas 78701 (US)
  • GOLLIHAR, JR., Jimmy Dale
    Houston, Texas 77006 (US)
  • BOUTZ, Daniel, Robert
    Austin, Texas 78729 (US)
  • SHROFF, Raghav
    Eugene, Oregon 97401 (US)
  • KAR, Shaunak
    Houston, Texas 77021 (US)
  • SEGALL-SHAPIRO, Thomas Hale
    Houston, Texas 77030 (US)
  • HORTON, Andrew Pitchford
    Houston, Texas 77004 (US)

(74) Representative: Studio Torta S.p.A. 
Via Viotti, 9
10121 Torino
10121 Torino (IT)

   


(54) ENHANCED LASSA FEVER VIRUS IMMUNOGENS